Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEREDITH ANN MCKEAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1437425659
CMS profile
2767983
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$34,451.12

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEREDITH ANN MCKEAN

NPI 1437425659 · CMS profile ID 2767983

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEREDITH ANN MCKEAN, NPI 1437425659, CMS profile ID 2767983. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MEREDITH ANN MCKEAN, NPI 1437425659, CMS profile ID 2767983. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MEREDITH ANN MCKEAN, NPI 1437425659, CMS profile ID 2767983, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $34,451.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $28.1808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086963418 CMS
Merck Sharp & Dohme LLC $29.4108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141903378 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.8408/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086115548 CMS
Eisai Inc. $22.3908/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110765297 CMS
E.R. Squibb & Sons, L.L.C. $18.0808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101736820 CMS
Iovance Biotherapeutics, Inc. $22.3308/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147113416 CMS
Regeneron Healthcare Solutions, Inc. $8.4708/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114112101 CMS
E.R. Squibb & Sons, L.L.C. $1,875.0008/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101736810 CMS
AstraZeneca Pharmaceuticals LP $29.1608/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105252373 CMS
Daiichi Sankyo Inc. $22.3407/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455176 CMS
Kyowa Kirin, Inc. $16.3607/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127037422 CMS
Regeneron Healthcare Solutions, Inc. $90.1707/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114112099 CMS
Exelixis Inc. $14.8307/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138561874 CMS
Merck Sharp & Dohme LLC $31.9806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141947643 CMS
Daiichi Sankyo Inc. $29.5606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455174 CMS
Genentech USA, Inc. $17.7406/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133068743 CMS
Incyte Corporation $21.9006/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141311471 CMS
Celgene Corporation $18.8706/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101179642 CMS
Novartis Pharmaceuticals Corporation $28.4606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086963416 CMS
E.R. Squibb & Sons, L.L.C. $17.3906/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101736784 CMS
Janssen Biotech, Inc. $20.7206/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078671234 CMS
PFIZER INC. $150.0006/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131461785 CMS
Delcath Systems $118.0605/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130859330 CMS
Regeneron Healthcare Solutions, Inc. $8.7105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114112097 CMS
ARRAY BIOPHARMA INC $630.0005/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131597486 CMS
Genmab U.S., Inc. $21.4605/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126829704 CMS
Immunocore Limited $125.2005/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103097207 CMS
Merck Sharp & Dohme LLC $31.3704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141801360 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $17.8304/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152182083 CMS
AstraZeneca Pharmaceuticals LP $32.8704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105544727 CMS
F. Hoffmann-La Roche AG $845.3404/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133068747 CMS
F. Hoffmann-La Roche AG $155.6204/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133068751 CMS
F. Hoffmann-La Roche AG $279.4604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133068755 CMS
F. Hoffmann-La Roche AG $9,423.6104/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133068759 CMS
F. Hoffmann-La Roche AG $103.5404/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133068763 CMS
Daiichi Sankyo Inc. $28.4804/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455172 CMS
Immunocore Limited $122.2704/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103097125 CMS
Daiichi Sankyo Inc. $17.6103/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455170 CMS
Verity Pharmaceuticals Inc. $21.3203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080605918 CMS
Alexion Pharmaceuticals, Inc. $22.5203/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093890903 CMS
Deciphera Pharmaceuticals Inc. $22.3403/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145874159 CMS
Lilly USA, LLC $31.7803/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135171502 CMS
Novartis Pharmaceuticals Corporation $31.8802/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086963414 CMS
Regeneron Healthcare Solutions, Inc. $27.0502/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114112095 CMS
Delcath Systems $154.0002/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130859728 CMS
AstraZeneca Pharmaceuticals LP $19.4402/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105429615 CMS
Daiichi Sankyo Inc. $2,055.0002/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455164 CMS
Merck Sharp & Dohme LLC $24.0302/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141903376 CMS
AstraZeneca Pharmaceuticals LP $20.3402/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105759343 CMS
Gilead Sciences, Inc. $22.8602/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133841916 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,551.63 42
PY2020 $1,985.86 5
PY2021 $4,888.92 12
PY2022 $768.96 21
PY2023 $22,449.82 83
PY2024 $34,451.12 106
PY2025 $43,251.70 120

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,210.81 9
PY2025 Principal investigator $2,968,025.66 971
PY2024 Recipient $10,299.19 10
PY2024 Principal investigator $2,203,641.66 817
PY2023 Recipient $12,628.46 43
PY2023 Principal investigator $2,492,754.75 523
PY2022 Recipient $5,501.69 17
PY2022 Principal investigator $4,173,649.03 571
PY2021 Recipient $6,391.30 7
PY2021 Principal investigator $2,633,751.67 317
PY2020 Principal investigator $1,227,757.68 85
PY2019 Principal investigator $202,429.12 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

980 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $2,000.00 12/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304833
Principal investigator 1 Ipsen Pharma SAS $1,000.00 12/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304835
Principal investigator 1 BioNTech SE $1,850.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152 No dispute reported 06/30/2026 1249019566
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,426.30 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498613
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,596.05 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184279354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184279390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,700.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184279442
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,977.80 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043444
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,546.45 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043446
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $375.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043448
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043450
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 12/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816968
Principal investigator 1 Ipsen Pharma SAS $4,542.75 12/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304829
Principal investigator 1 Ipsen Pharma SAS $3,206.25 12/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304831
Principal investigator 1 ModernaTX, Inc. $850.00 12/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968633
Principal investigator 1 PFIZER INC. $3,000.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228745712
Principal investigator 1 Ipsen Pharma SAS $4,320.00 12/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184276254
Principal investigator 1 Iovance Biotherapeutics, Inc. $9,210.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498517
Principal investigator 1 Iovance Biotherapeutics, Inc. $7,000.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498605
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498631
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,850.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498669
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 12/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,863.00 12/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274803
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $36,667.35 12/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043442
Principal investigator 1 Genentech, Inc. $562.50 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649955
Principal investigator 1 Genentech, Inc. $1,095.75 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184268697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184268699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184268701
Principal investigator 1 SANOFI US SERVICES INC. $300.00 12/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081787
Principal investigator 1 SANOFI US SERVICES INC. $300.00 12/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082345
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655734
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,200.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184267301
Principal investigator 1 Ipsen Pharma SAS $5,444.55 11/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304777
Principal investigator 1 Ipsen Pharma SAS $3,461.40 11/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304779
Principal investigator 1 Ipsen Pharma SAS $6,228.90 11/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 11/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184265917
Principal investigator 1 PFIZER INC. $6,693.30 11/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228728123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,723.95 11/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184264375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,119.50 11/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184264381
Principal investigator 1 PFIZER INC. $1,450.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228728409
Principal investigator 1 SANOFI US SERVICES INC. $2,106.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184263359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184263361
Principal investigator 1 ModernaTX, Inc. $2,500.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968631
Principal investigator 1 ModernaTX, Inc. $750.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968657
Principal investigator 1 Ipsen Pharma SAS $4,542.75 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304767
Principal investigator 1 Ipsen Pharma SAS $4,263.30 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304769
Principal investigator 1 Ipsen Pharma SAS $2,596.05 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304771
Principal investigator 1 Ipsen Pharma SAS $2,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304773
Principal investigator 1 Ipsen Pharma SAS $1,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304775
Principal investigator 1 Ipsen Pharma SAS $3,206.25 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304781
Principal investigator 1 Ipsen Pharma SAS $116.10 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304785
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043440
Principal investigator 1 PFIZER INC. $1,250.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228730130
Principal investigator 1 ModernaTX, Inc. $2,500.00 11/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968629
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081791
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081800
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081805
Principal investigator 1 SANOFI US SERVICES INC. $137.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081809
Principal investigator 1 SANOFI US SERVICES INC. $56.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081814
Principal investigator 1 SANOFI US SERVICES INC. $102.02 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081822
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081826
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081830
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081832
Principal investigator 1 SANOFI US SERVICES INC. $71.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081835
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081839
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081844
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081847
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081851
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081856
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081881
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081885
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081889
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081892
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081896
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081899
Principal investigator 1 SANOFI US SERVICES INC. $13.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081903
Principal investigator 1 SANOFI US SERVICES INC. $125.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081907
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081911
Principal investigator 1 SANOFI US SERVICES INC. $13.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081915
Principal investigator 1 SANOFI US SERVICES INC. $125.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081919
Principal investigator 1 SANOFI US SERVICES INC. $60.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082026
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082030
Principal investigator 1 SANOFI US SERVICES INC. $60.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082038
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082043
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082047
Principal investigator 1 SANOFI US SERVICES INC. $137.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082051
Principal investigator 1 SANOFI US SERVICES INC. $13.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082056
Principal investigator 1 SANOFI US SERVICES INC. $56.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082059
Principal investigator 1 SANOFI US SERVICES INC. $125.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082064
Principal investigator 1 SANOFI US SERVICES INC. $102.02 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082068
Principal investigator 1 SANOFI US SERVICES INC. $137.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082072
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082076
Principal investigator 1 SANOFI US SERVICES INC. $56.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082080
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082082
Principal investigator 1 SANOFI US SERVICES INC. $102.02 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082084
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082087
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082091
Principal investigator 1 SANOFI US SERVICES INC. $71.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082095
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082098
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082103
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082106
Principal investigator 1 SANOFI US SERVICES INC. $71.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082110
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082114
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082119
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082122
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082127
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082132
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082136
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082140
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082144
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082148
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082152
Principal investigator 1 SANOFI US SERVICES INC. $137.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082156
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082160
Principal investigator 1 SANOFI US SERVICES INC. $56.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082164
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082169
Principal investigator 1 SANOFI US SERVICES INC. $102.02 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082173
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082177
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082180
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082184
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082188
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082193
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082197
Principal investigator 1 SANOFI US SERVICES INC. $71.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082201
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082205
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082209
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082217
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082229
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082237
Principal investigator 1 SANOFI US SERVICES INC. $71.25 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082245
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082254
Principal investigator 1 SANOFI US SERVICES INC. $112.20 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082261
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082271
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082283
Principal investigator 1 SANOFI US SERVICES INC. $137.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082292
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082305
Principal investigator 1 SANOFI US SERVICES INC. $43.75 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082317
Principal investigator 1 SANOFI US SERVICES INC. $75.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082329
Principal investigator 1 SANOFI US SERVICES INC. $37.50 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082341
Principal investigator 1 SANOFI US SERVICES INC. $40.00 11/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226082350
Principal investigator 1 PFIZER INC. $1,250.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228737581
Principal investigator 1 BioNTech SE $1,850.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152 No dispute reported 06/30/2026 1249019564
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184257771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184257773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,700.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184258045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043436
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.73 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043438
Principal investigator 1 PFIZER INC. $11,510.00 11/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228724384
Principal investigator 1 PFIZER INC. $48,789.50 11/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228737745
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498615
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498617
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498619
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498633
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498635
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498637
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,400.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498639
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655732
Principal investigator 1 Ipsen Pharma SAS $5,196.15 10/31/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304751
Principal investigator 1 Ipsen Pharma SAS $5,706.45 10/31/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304753
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252498629
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252498649
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252498661
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252498667
Principal investigator 1 Ipsen Pharma SAS $1,000.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304749
Principal investigator 1 Ipsen Pharma SAS $2,000.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,863.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,550.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184253893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,700.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184253895
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,358.20 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043434
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816964
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,781.40 10/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043432
Principal investigator 1 Iovance Biotherapeutics, Inc. $9,050.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252498627
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,187.80 10/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043430
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382842
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382846
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382848
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382850
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382854
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382856
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382858
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382860
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382862
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382866
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382870
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382874
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382876
Principal investigator 1 Daiichi Sankyo Inc. $89.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382880
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382882
Principal investigator 1 Daiichi Sankyo Inc. $89.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382884
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382886
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382888
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382890
Principal investigator 1 Genentech, Inc. $2,500.00 10/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,349.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184249122
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,260.65 10/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043427
Principal investigator 1 Genentech, Inc. $2,500.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649895
Principal investigator 1 Iovance Biotherapeutics, Inc. $20,341.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498469
Principal investigator 1 PFIZER INC. $3,000.00 10/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228723538
Principal investigator 1 PFIZER INC. $4,325.00 10/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228730529
Principal investigator 1 Iovance Biotherapeutics, Inc. $15,000.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498609
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,000.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498611
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,850.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498653
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,850.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498663
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,383.15 10/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043425
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 10/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816960
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,075.00 10/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816962
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382844
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382852
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382868
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382872
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382878
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655730
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,750.00 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498621
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,750.00 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252498651
Principal investigator 1 Genentech, Inc. $2,500.00 09/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649832
Principal investigator 1 BioNTech SE $1,850.00 09/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019624
Principal investigator 1 BioNTech SE $2,135.00 09/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019634
Principal investigator 1 BioNTech SE $40.00 09/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019638
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,094.35 09/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043423
Principal investigator 1 Daiichi Sankyo Inc. $6,626.11 09/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382618
Principal investigator 1 Daiichi Sankyo Inc. $5,011.60 09/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382620
Principal investigator 1 Ipsen Pharma SAS $1,000.00 09/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304727
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184240282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184240284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184240286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184240288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184240290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,723.95 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,092.50 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184240758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,000.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184240768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,400.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,420.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184240788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184240790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,700.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184240794
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,323.45 09/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043417
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,772.60 09/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043419
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 09/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043421
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382586
Principal investigator 1 Daiichi Sankyo Inc. $500.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382588
Principal investigator 1 PFIZER INC. $2,700.00 09/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228752938
Principal investigator 1 PFIZER INC. $3,000.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE SGNCEACAM5C IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228757757
Principal investigator 1 PFIZER INC. $1,250.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228757914
Principal investigator 1 Genentech, Inc. $2,500.00 09/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649828
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,900.00 09/11/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1190310162
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968635
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968643
Principal investigator 1 PFIZER INC. $6,000.00 09/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228759617
Recipient Regeneron Pharmaceuticals, Inc. $258.14 09/10/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120197
Principal investigator 1 PFIZER INC. $16,242.60 09/09/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228714132
Principal investigator 1 PFIZER INC. $16,242.60 09/09/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville Sarah Cannon Research Inst Pharmacy
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228719243
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968647
Principal investigator 1 BioNTech SE $1,850.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019695
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,859.15 09/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043415
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383500
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383502
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383504
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383506
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383508
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383510
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383512
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383514
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383516
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383518
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383520
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383522
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383524
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383526
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383528
Principal investigator 1 Daiichi Sankyo Inc. $112.75 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383530
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383532
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383534
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383536
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383538
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383540
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383542
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383544
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383546
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383548
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383550
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383552
Principal investigator 1 Daiichi Sankyo Inc. $45.10 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383554
Principal investigator 1 Daiichi Sankyo Inc. $22.55 09/03/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383556
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968649
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968655
Principal investigator 1 PFIZER INC. $1,250.00 09/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228760428
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184233434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184233436
Principal investigator 1 Merck Sharp & Dohme LLC $83,025.68 08/31/2025 Non-covered Recipient Entity
SCRI Oncology Partners
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 No dispute reported 06/30/2026 1232933500
Recipient Regeneron Pharmaceuticals, Inc. $104.73 08/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120195
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816958
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304689
Principal investigator 1 Ipsen Pharma SAS $1,000.00 08/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304699
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304701
Principal investigator 1 Ipsen Pharma SAS $1,000.00 08/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304703
Principal investigator 1 Ipsen Pharma SAS $1,500.00 08/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304705
Principal investigator 1 PFIZER INC. $21,990.00 08/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228722992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,834.65 08/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184230511
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968639
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,260.65 08/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043413
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382582
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382592
Principal investigator 1 Daiichi Sankyo Inc. $500.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382596
Principal investigator 1 Daiichi Sankyo Inc. $500.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382598
Principal investigator 1 Daiichi Sankyo Inc. $500.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382600
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382602
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382604
Principal investigator 1 Daiichi Sankyo Inc. $500.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382606
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382608
Principal investigator 1 Daiichi Sankyo Inc. $85.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382610
Principal investigator 1 Daiichi Sankyo Inc. $85.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382612
Principal investigator 1 Daiichi Sankyo Inc. $89.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382614
Principal investigator 1 Daiichi Sankyo Inc. $85.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382616
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382808
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382826
Principal investigator 1 Daiichi Sankyo Inc. $85.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,741.20 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228485
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,772.60 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043409
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043411
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,772.60 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043500
Principal investigator 1 Ipsen Pharma SAS $2,300.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304687
Principal investigator 1 Ipsen Pharma SAS $15,000.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304691
Principal investigator 1 Ipsen Pharma SAS $5,000.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304693
Principal investigator 1 Ipsen Pharma SAS $3,500.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304697
Principal investigator 1 Ipsen Pharma SAS $2,300.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304707
Principal investigator 1 Ipsen Pharma SAS $2,300.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304709
Principal investigator 1 BioNTech SE $747.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019632
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655726
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382584
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382590
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382594
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382804
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382806
Principal investigator 1 Daiichi Sankyo Inc. $41,536.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382810
Principal investigator 1 Daiichi Sankyo Inc. $36,344.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382812
Principal investigator 1 Daiichi Sankyo Inc. $36,344.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382814
Principal investigator 1 Daiichi Sankyo Inc. $10,278.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382816
Principal investigator 1 Daiichi Sankyo Inc. $10,900.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382818
Principal investigator 1 Iovance Biotherapeutics, Inc. $131,800.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252497679
Principal investigator 1 Iovance Biotherapeutics, Inc. $8,550.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252497883
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,500.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252497885
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,850.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252497887
Principal investigator 1 Ipsen Pharma SAS $500.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184223066
Principal investigator 1 BioNTech SE $2,057.40 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019628
Principal investigator 1 Daiichi Sankyo Inc. $5,439.06 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382580
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382790
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382792
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382794
Principal investigator 1 Daiichi Sankyo Inc. $2,125.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382796
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382798
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382800
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382802
Principal investigator 1 ModernaTX, Inc. $2,500.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968653
Principal investigator 1 PFIZER INC. $1,081.35 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228783418
Principal investigator 1 PFIZER INC. $8,010.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228790578
Principal investigator 1 PFIZER INC. $3,000.00 07/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228763153
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382576
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382578
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382622
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382624
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382626
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382628
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382630
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382632
Principal investigator 1 Daiichi Sankyo Inc. $432.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382634
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382636
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382638
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382640
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382642
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382644
Principal investigator 1 Daiichi Sankyo Inc. $432.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382646
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382648
Principal investigator 1 Daiichi Sankyo Inc. $432.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382650
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382652
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382654
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382656
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382658
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382660
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382662
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382664
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382666
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382668
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382670
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382672
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382674
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382676
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382678
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382680
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382682
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382684
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382686
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382688
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382690
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382692
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382694
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382696
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382698
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382700
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382702
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382704
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382706
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382708
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382710
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382712
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382714
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382716
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382718
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382720
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382722
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382724
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382726
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382728
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382730
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382732
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382734
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382736
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382738
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382740
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382742
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382744
Principal investigator 1 Daiichi Sankyo Inc. $89.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382746
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382748
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382750
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382752
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382754
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382756
Principal investigator 1 Daiichi Sankyo Inc. $500.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382758
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382760
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382762
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382764
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382766
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382768
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382770
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382772
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382774
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382776
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382778
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382780
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382782
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382784
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382786
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382788
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382820
Principal investigator 1 Daiichi Sankyo Inc. $89.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382822
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382824
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382828
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382830
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382832
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382834
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382836
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382840
Principal investigator 1 Genentech, Inc. $2,500.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649824
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,525.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252497897
Principal investigator 1 PFIZER INC. $3,248.52 07/21/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228714134
Principal investigator 1 PFIZER INC. $3,248.52 07/21/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville Sarah Cannon Research Inst Pharmacy
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228719246
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228720489
Principal investigator 1 Genentech, Inc. $2,500.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649834
Principal investigator 1 BioNTech SE $39,432.60 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 07/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184214894
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,200.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
133421 No dispute reported 06/30/2026 1252497881
Principal investigator 1 BioNTech SE $40.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019636
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,000.00 07/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043407
Principal investigator 1 BioNTech SE $3,466.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019630
Principal investigator 1 BioNTech SE $1,850.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184213071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184213073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184213081
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,750.00 07/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043403
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 07/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043405
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655724
Principal investigator 1 PFIZER INC. $3,000.00 07/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228723560
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $850.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,800.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184212231
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 06/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816954
Principal investigator 1 Epizyme, Inc. $48,879.50 06/26/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184281964
Principal investigator 1 Epizyme, Inc. $7,974.75 06/26/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184281966
Principal investigator 1 PFIZER INC. $1,737.45 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228777189
Principal investigator 1 Daiichi Sankyo Inc. $523.55 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382514
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382516
Principal investigator 1 Daiichi Sankyo Inc. $44.55 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382518
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382520
Principal investigator 1 Daiichi Sankyo Inc. $899.10 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382522
Principal investigator 1 Daiichi Sankyo Inc. $500.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382524
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382526
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382550
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382552
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382556
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382566
Principal investigator 1 Iovance Biotherapeutics, Inc. $10,500.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496213
Principal investigator 1 Iovance Biotherapeutics, Inc. $996.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496215
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,900.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496217
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496221
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,000.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496223
Principal investigator 1 Iovance Biotherapeutics, Inc. $15,000.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496225
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496229
Principal investigator 1 PFIZER INC. $1,250.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228791731
Principal investigator 1 Daiichi Sankyo Inc. $89.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 06/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184209916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 06/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184209918
Principal investigator 1 BioNTech SE $2,621.70 06/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 06/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184209322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 06/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184209324
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 06/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043397
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 06/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043399
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,000.00 06/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244043401
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184207189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184207191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,825.20 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184207235
Principal investigator 1 SANOFI US SERVICES INC. $177,799.73 06/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081985
Principal investigator 1 PFIZER INC. $8,010.00 06/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228791415
Principal investigator 1 BioNTech SE $1,850.00 06/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019614
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,000.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
117145 No dispute reported 06/30/2026 1252496227
Recipient Regeneron Pharmaceuticals, Inc. $119.77 06/06/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120193
Principal investigator 1 BioNTech SE $457.20 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,000.00 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204419
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968641
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968645
Principal investigator 1 Genentech, Inc. $1,390.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1211651139
Principal investigator 1 PFIZER INC. $2,525.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228786581
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655722
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,500.00 06/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816950
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 06/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816952
Principal investigator 1 Genentech, Inc. $2,500.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649796
Principal investigator 1 BioNTech SE $2,941.20 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019588
Principal investigator 1 Epizyme, Inc. $588.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184281968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184199065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,042.20 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,737.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,825.20 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,825.20 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184199633
Principal investigator 1 BioNTech SE $1,850.00 05/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019610
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382548
Principal investigator 1 PFIZER INC. $753.00 05/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228765064
Principal investigator 1 PFIZER INC. $1,250.00 05/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228773541
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382532
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382534
Principal investigator 1 Daiichi Sankyo Inc. $366.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382536
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382538
Principal investigator 1 Daiichi Sankyo Inc. $2,180.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382540
Principal investigator 1 Daiichi Sankyo Inc. $366.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382542
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382544
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382546
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382558
Principal investigator 1 Genentech, Inc. $2,500.00 05/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649806
Principal investigator 1 PFIZER INC. $6,363.90 05/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228774241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 05/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197767
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382408
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382410
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382412
Principal investigator 1 Daiichi Sankyo Inc. $1,572.75 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382414
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382416
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382418
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382420
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382422
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382424
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382426
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382428
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382430
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382432
Principal investigator 1 Daiichi Sankyo Inc. $2,180.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382434
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382436
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382438
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382504
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382506
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382508
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382510
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382512
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382560
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382572
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382502
Principal investigator 1 Genentech, Inc. $2,500.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649802
Principal investigator 1 Genentech, Inc. $2,500.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649811
Principal investigator 1 BioNTech SE $3,245.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019360
Principal investigator 1 BioNTech SE $590.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019362
Principal investigator 1 BioNTech SE $2,185.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019364
Principal investigator 1 BioNTech SE $1,250.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019366
Principal investigator 1 BioNTech SE $960.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019368
Principal investigator 1 BioNTech SE $390.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019370
Principal investigator 1 BioNTech SE $1,345.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019372
Principal investigator 1 BioNTech SE $1,525.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019374
Principal investigator 1 BioNTech SE $6,695.00 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019376
Principal investigator 1 BioNTech SE $29,794.28 05/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019378
Principal investigator 1 Ipsen Pharma SAS $147.00 05/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304633
Principal investigator 1 PFIZER INC. $900.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228764693
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 05/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816948
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382376
Principal investigator 1 Daiichi Sankyo Inc. $2,180.00 05/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382378
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 05/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382380
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 05/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382382
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816946
Principal investigator 1 Ipsen Pharma SAS $24.50 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304635
Principal investigator 1 BioNTech SE $1,540.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019380
Principal investigator 1 BioNTech SE $1,990.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019382
Principal investigator 1 BioNTech SE $180.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT151-01 No dispute reported 06/30/2026 1249019384
Principal investigator 1 BioNTech SE $2,621.70 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019408
Principal investigator 1 BioNTech SE $588.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019598
Principal investigator 1 BioNTech SE $1,850.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019604
Principal investigator 1 BioNTech SE $2,621.70 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184193405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184193407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184193409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184193411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184193413
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655720
Principal investigator 1 Ipsen Pharma SAS $60.00 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304729
Principal investigator 1 Ipsen Pharma SAS $70.00 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184191271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184191273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184191275
Recipient Regeneron Pharmaceuticals, Inc. $292.81 04/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120191
Principal investigator 1 PFIZER INC. $18,612.45 04/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228780561
Principal investigator 1 SANOFI US SERVICES INC. $9,554.11 04/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226081982
Principal investigator 1 Daiichi Sankyo Inc. $3,061.80 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382476
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382478
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382480
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382482
Principal investigator 1 Daiichi Sankyo Inc. $1,377.00 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382484
Principal investigator 1 Daiichi Sankyo Inc. $1,572.75 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382486
Principal investigator 1 Daiichi Sankyo Inc. $3,812.40 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382488
Principal investigator 1 Daiichi Sankyo Inc. $3,812.40 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382490
Principal investigator 1 Daiichi Sankyo Inc. $1,572.75 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382492
Principal investigator 1 Daiichi Sankyo Inc. $1,377.00 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382494
Principal investigator 1 Daiichi Sankyo Inc. $3,812.40 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382496
Principal investigator 1 Daiichi Sankyo Inc. $1,572.75 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382498
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382500
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382528
Principal investigator 1 Daiichi Sankyo Inc. $1,377.00 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382530
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382554
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382562
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 04/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382574
Principal investigator 1 Ipsen Pharma SAS $73.07 04/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304619
Principal investigator 1 Ipsen Pharma SAS $72.40 04/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304621
Principal investigator 1 Ipsen Pharma SAS $69.28 04/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304627
Principal investigator 1 Ipsen Pharma SAS $639.01 04/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304629
Principal investigator 1 Ipsen Pharma SAS $85.99 04/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304631
Principal investigator 1 PFIZER INC. $4,211.25 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228780467
Principal investigator 1 PFIZER INC. $2,946.28 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT No dispute reported 06/30/2026 1228798598
Principal investigator 1 BioNTech SE $3,169.80 04/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184183372
Principal investigator 1 PFIZER INC. $596.00 04/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228779469
Principal investigator 1 PFIZER INC. $1,250.00 04/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228796483
Principal investigator 1 PFIZER INC. $7,764.00 04/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228779014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184182000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184182002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184181894
Principal investigator 1 PFIZER INC. $5,290.65 04/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228780939
Recipient Regeneron Pharmaceuticals, Inc. $396.99 04/05/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120189
Recipient Regeneron Pharmaceuticals, Inc. $396.52 04/03/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120187
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382374
Principal investigator 1 Daiichi Sankyo Inc. $3,061.80 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382384
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382386
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382388
Principal investigator 1 Daiichi Sankyo Inc. $3,061.80 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382390
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382392
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382394
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382396
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382398
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382400
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382402
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382404
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382406
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382440
Principal investigator 1 Daiichi Sankyo Inc. $773.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382442
Principal investigator 1 Daiichi Sankyo Inc. $1,572.75 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382444
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382446
Principal investigator 1 Daiichi Sankyo Inc. $1,377.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382448
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382452
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382454
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382456
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382458
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382460
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382462
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382464
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382466
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382468
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382470
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382472
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382474
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382564
Principal investigator 1 Daiichi Sankyo Inc. $3,061.80 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382568
Principal investigator 1 Daiichi Sankyo Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382570
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655718
Principal investigator 1 Epizyme, Inc. $70.00 04/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184283095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184180516
Principal investigator 1 PFIZER INC. $32,485.20 03/31/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228761498
Principal investigator 1 PFIZER INC. $2,500.00 03/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228724452
Principal investigator 1 PFIZER INC. $22,115.00 03/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228797783
Principal investigator 1 Aadi Bioscience, Inc. $1,031.05 03/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946821
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 03/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816944
Principal investigator 1 Epizyme, Inc. $1,100.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma No dispute reported 06/30/2026 1184283011
Principal investigator 1 PFIZER INC. $1,250.00 03/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228783895
Principal investigator 1 PFIZER INC. $1,250.00 03/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228787999
Principal investigator 1 PFIZER INC. $4,000.00 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228780534
Principal investigator 1 PFIZER INC. $4,692.60 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228787668
Principal investigator 1 BioNTech SE $60,516.90 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184174352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184174354
Principal investigator 1 Genentech, Inc. $3,199.50 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649572
Principal investigator 1 Genentech, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184172612
Principal investigator 1 BioNTech SE $40.00 03/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019735
Principal investigator 1 BioNTech SE $1,850.00 03/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019737
Principal investigator 1 SANOFI US SERVICES INC. $2,189.64 03/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst Llc
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1226084831
Principal investigator 1 Epizyme, Inc. $732.00 03/10/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184281954
Principal investigator 1 PFIZER INC. $1,250.00 03/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228779905
Principal investigator 1 PFIZER INC. $12,601.24 03/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228797065
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382960
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382962
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382964
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382966
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382968
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382970
Principal investigator 1 Daiichi Sankyo Inc. $3,568.05 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382972
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382974
Principal investigator 1 Daiichi Sankyo Inc. $3,568.05 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382976
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382978
Principal investigator 1 Daiichi Sankyo Inc. $3,568.05 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382980
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382984
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382986
Principal investigator 1 Daiichi Sankyo Inc. $3,568.05 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382988
Principal investigator 1 Daiichi Sankyo Inc. $3,568.05 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382990
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383056
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383058
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383064
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383070
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383072
Principal investigator 1 Genentech, Inc. $2,500.00 03/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1211650310
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655714
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 03/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816942
Principal investigator 1 Epizyme, Inc. $70.00 03/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184283019
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $279.84 02/25/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
DLL3CD3 phIb in glioma for PoCP No dispute reported 06/30/2026 1220995520
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $299.70 02/25/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
DLL3CD3 phIb in glioma for PoCP No dispute reported 06/30/2026 1220995522
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.00 02/25/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
DLL3CD3 phIb in glioma for PoCP No dispute reported 06/30/2026 1220995524
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10.80 02/25/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
DLL3CD3 phIb in glioma for PoCP No dispute reported 06/30/2026 1220995526
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4.23 02/25/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
DLL3CD3 phIb in glioma for PoCP No dispute reported 06/30/2026 1220995528
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.28 02/25/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
DLL3CD3 phIb in glioma for PoCP No dispute reported 06/30/2026 1220995530
Principal investigator 1 PFIZER INC. $4,692.60 02/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228758867
Recipient Regeneron Pharmaceuticals, Inc. $148.22 02/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120185
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382892
Principal investigator 1 Daiichi Sankyo Inc. $6,230.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382894
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382896
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382898
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382900
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382902
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382904
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382906
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382908
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382910
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382912
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382914
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382916
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382918
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382920
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382922
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382924
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382926
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382928
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382930
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382932
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382934
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382936
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382938
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382940
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382942
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382944
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382946
Principal investigator 1 Daiichi Sankyo Inc. $2,180.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382948
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382950
Principal investigator 1 Daiichi Sankyo Inc. $3,426.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382952
Principal investigator 1 Daiichi Sankyo Inc. $6,230.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382954
Principal investigator 1 Daiichi Sankyo Inc. $1,863.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382956
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382958
Principal investigator 1 Daiichi Sankyo Inc. $3,426.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383044
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383046
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383048
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383050
Principal investigator 1 Daiichi Sankyo Inc. $6,230.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383054
Principal investigator 1 Daiichi Sankyo Inc. $3,426.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383060
Principal investigator 1 Daiichi Sankyo Inc. $1,544.93 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383068
Principal investigator 1 PFIZER INC. $16,242.60 02/24/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228760220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 02/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184155118
Principal investigator 1 ModernaTX, Inc. $2,500.00 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184154680
Principal investigator 1 PFIZER INC. $23,551.77 02/18/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228769083
Recipient Regeneron Pharmaceuticals, Inc. $254.71 02/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120181
Recipient Regeneron Pharmaceuticals, Inc. $238.92 02/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184120183
Principal investigator 1 Aadi Bioscience, Inc. $3,000.00 02/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,915.00 02/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184153116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,733.00 02/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184153120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,913.00 02/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184153124
Principal investigator 1 BioNTech SE $1,850.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019731
Principal investigator 1 Genentech, Inc. $2,500.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649562
Principal investigator 1 PFIZER INC. $59,667.37 02/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228760134
Principal investigator 1 Daiichi Sankyo Inc. $112.75 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383118
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383134
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383138
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383140
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383142
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383144
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383146
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383148
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383150
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383152
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383154
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383156
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383158
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383160
Principal investigator 1 Daiichi Sankyo Inc. $22.55 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383162
Principal investigator 1 Daiichi Sankyo Inc. $22.55 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383164
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383166
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383168
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383170
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383172
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383174
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383176
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383178
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383180
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383182
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383184
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383186
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383188
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383190
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383192
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383194
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383196
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383210
Principal investigator 1 Daiichi Sankyo Inc. $112.75 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383224
Principal investigator 1 Daiichi Sankyo Inc. $45.10 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383236
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383248
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383250
Principal investigator 1 Daiichi Sankyo Inc. $90.20 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383254
Principal investigator 1 Daiichi Sankyo Inc. $67.65 02/04/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383256
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382992
Principal investigator 1 Daiichi Sankyo Inc. $5,124.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382994
Principal investigator 1 Daiichi Sankyo Inc. $1,656.45 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382996
Principal investigator 1 Daiichi Sankyo Inc. $3,061.80 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223382998
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383000
Principal investigator 1 Daiichi Sankyo Inc. $3,061.80 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383004
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383006
Principal investigator 1 Daiichi Sankyo Inc. $1,224.45 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383008
Principal investigator 1 Daiichi Sankyo Inc. $899.10 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383010
Principal investigator 1 Daiichi Sankyo Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383012
Principal investigator 1 Daiichi Sankyo Inc. $899.10 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383014
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383016
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383018
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383020
Principal investigator 1 Daiichi Sankyo Inc. $1,377.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383022
Principal investigator 1 Daiichi Sankyo Inc. $3,812.40 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383024
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383026
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383028
Principal investigator 1 Daiichi Sankyo Inc. $3,568.05 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383030
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383032
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383034
Principal investigator 1 Daiichi Sankyo Inc. $3,812.40 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383036
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383038
Principal investigator 1 Daiichi Sankyo Inc. $1,664.55 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383040
Principal investigator 1 Daiichi Sankyo Inc. $3,029.40 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383042
Principal investigator 1 Daiichi Sankyo Inc. $3,883.95 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383052
Principal investigator 1 Daiichi Sankyo Inc. $3,812.40 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383062
Principal investigator 1 Daiichi Sankyo Inc. $2,994.30 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-277 No dispute reported 06/30/2026 1223383066
Principal investigator 1 PFIZER INC. $2,525.00 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228724648
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,811.70 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184151597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,034.00 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184151599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,811.70 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184151601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,706.30 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184151603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,340.10 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184151605
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655712
Principal investigator 1 Epizyme, Inc. $70.00 02/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184283017
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 01/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816938
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 01/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816940
Principal investigator 1 PFIZER INC. $19,400.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228801146
Principal investigator 1 Genentech, Inc. $2,500.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649566
Principal investigator 1 Genentech, Inc. $1,740.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211649569
Principal investigator 1 PFIZER INC. $24,363.90 01/21/2025 Non-covered Recipient Entity
Tennessee Oncology Nashville
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228761492
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,200.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors No dispute reported 06/30/2026 1190303739
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,850.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1190304413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184148269
Principal investigator 1 Genentech, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1211650387
Principal investigator 1 Novartis Pharmaceuticals Corporation $57.44 01/15/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1190310164
Principal investigator 1 PFIZER INC. $21,500.00 01/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228800602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184147553
Principal investigator 1 BioNTech SE $1,850.00 01/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT152-01C No dispute reported 06/30/2026 1249019727
Principal investigator 1 Epizyme, Inc. $8,380.02 01/08/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184281952
Principal investigator 1 ModernaTX, Inc. $2,500.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252968651
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,040.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma No dispute reported 06/30/2026 1190304479
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,685.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer No dispute reported 06/30/2026 1190304435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184146064
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,275.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220816936
Principal investigator 1 Daiichi Sankyo Inc. $17.60 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383116
Principal investigator 1 Daiichi Sankyo Inc. $250.00 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383120
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383122
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383124
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383126
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383128
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383130
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383132
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383136
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383198
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383200
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383202
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383204
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383206
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383208
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383212
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383214
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383216
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383218
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383220
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383222
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383226
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383228
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383230
Principal investigator 1 Daiichi Sankyo Inc. $39.00 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383232
Principal investigator 1 Daiichi Sankyo Inc. $45.10 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383234
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383238
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383240
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383242
Principal investigator 1 Daiichi Sankyo Inc. $67.65 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383244
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383246
Principal investigator 1 Daiichi Sankyo Inc. $112.75 01/02/2025 Non-covered Recipient Entity
SCRI Oncology Partners
U31402-277 No dispute reported 06/30/2026 1223383252
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Tennessee Oncology Ste 200
A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 No dispute reported 06/30/2026 1220655716
Principal investigator 1 Epizyme, Inc. $70.00 01/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184283015
Principal investigator 1 Novartis Pharmaceuticals Corporation $140.00 01/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer No dispute reported 06/30/2026 1190306509